Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 5NETWORK 5NIH 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 31Lymphoma, Non-Hodgkin 20Lymphoma, Follicular 19Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, B-Cell 11Neoplasms 10Recurrence 8Lymphoma, Mantle-Cell 7Lymphoma, T-Cell, Peripheral 6Leukemia 5Hematologic Diseases 5Sarcoma, Kaposi 3Neuroblastoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3HIV Infections 3Acquired Immunodeficiency Syndrome 3Wilms Tumor 2Small Cell Lung Carcinoma 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Burkitt Lymphoma 2Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

Temozolomide 4Flucytosine 4vocimagene amiretrorepvec 3vorasidenib 2trametinib 2paclitaxel-Angiopep-2 conjugate 2dabrafenib 2Surgical Procedures, Operative 2OKN 007 2Chlorotoxin 2Carmustine 2talampanel 1selinexor 1pemigatinib 1pembrolizumab 1olutasidenib 1motexafin gadolinium 1exatecan 1Vincristine 1Radiation 1PF-06840003 1ONC206 1O(6)-benzylguanine 1Metabolism 1IL13-PE38 1Genetic Therapy 1Genetic Engineering 1Filgrastim 1Fentanyl 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Oligodendroglioma × Vincristine × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡